Approximately 30% of patients with mesial temporal lobe epilepsy do not respond to treatment with antiepileptic drugs. We have previously shown that transplantation of mononuclear bone marrow cells (BMC) has an anticonvulsant effect in acute epilepsy. Here, we used pilocarpine to induce epilepsy in rats and studied the effects of BMC injected intravenously either at the onset of seizures or after 10 months of recurrent seizures. BMC effectively decreased seizure frequency and duration. In addition, decreased levels of proinflammatory cytokines (TNF-α, IL-1β and IL-6) and increased levels of anti-inflammatory cytokine (IL-10) were observed in the brain and serum of BMC-treated rats. Transplants performed at seizure-onset protected against pilocarpine-induced neuronal loss and gliosis and stimulated the proliferation of new neurons in epileptic rats. Our data demonstrate that BMC transplantation has potent therapeutic effects and could be a potential therapy for clinically intractable epilepsies.
Introduction
Temporal lobe epilepsy (TLE) is the most common type of epilepsy in adults (Engel, 1996) . Mesial temporal epilepsy is a subtype of TLE associated with hippocampal sclerosis (Engel, 2001a; Wieser, 2004) and is one of the most frequent types of drug-resistant epilepsy (Engel, 2001a (Engel, , 2001b . Clinical and neuropathological findings support the hypothesis that TLE with hippocampal sclerosis develops in 3 phases: a postnatal initial precipitating injury, a latent period corresponding to epileptogenesis, and the occurrence of spontaneous recurrent seizures (SRS; Mathern et al., 1996) . In rats, status epilepticus (SE) induced by the systemic injection of the muscarinic receptor agonist pilocarpine is followed by a seizure-free period (latent phase) prior to the onset of SRS (Turski et al., 1987) . SRS is accompanied by hippocampal cell loss, axon sprouting (Mello et al., 1993) , and increased neurogenesis (Parent et al., 1997) . In recent years, reports have suggested that inflammatory processes in the brain contributes to epilepsy and seizure recurrence (Vezzani and Granata, 2005; Vezzani et al., 2008) .
Due to its focal nature and associated tissue degeneration, TLE is an attractive target for cell therapy applications. The bone marrow mononuclear cell fraction (BMC) contains populations of mesenchymal and hematopoietic stem cells that secrete a host of cytokines and growth factors involved in natural repair processes (Takahashi et al., 2006) . A contribution of BMC to the regeneration of brain injuries has been already demonstrated (Brazelton et al., 2000; Eglitis and Mezey, 1997) . In a rodent brain ischemia model, BMC (Baker et al., 2007; Brenneman et al., 2010; de Vasconcelos dos Santos et al., 2010; Giraldi-Guimarães et al., 2009; Iihoshi et al., 2004; Kamiya et al., 2008) and/or mesenchymal stem cells (Bao et al., 2011; Chopp and Li, 2002; Hu et al., 2004; Liu et al., 2009; Zacharek et al., 2010) were highly effective in promoting functional neurological recovery. In the clinical trials of cell-based therapies already performed, the results were highly promising in stroke and spinal cord injury (see review by Walker et al., 2010) .
In epileptic models, we demonstrated that BMC transplantation immediately after SE prevents the chronic seizure development, reduces neuronal loss, and influences reorganization of the hippocampal neuronal network (Costa-Ferro et al., 2010) . Neurobiology of Disease 46 (2012) 302-313 
